7116-47-4

Upstream product

• 40950-94-5 ethyl (E)-3-(3,4-dichloro-phenyl)-2-propenoate 
• 40950-94-5 3-(3,4-dichloro-phenyl)-acrylic acid ethyl ester 
• 1202-39-7 3,4-dichlorocinnamic acid 
• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 6287-38-3 3,4-dichlorobenzaldehyde 

Downstream Products

• 63204-34-2 5-(3,4-dichloro-benzyl)-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one 
• 20795-47-5 3-(3,4-dichlorophenyl)propanal 
• 39960-05-9 3-(3 ,4-dichlorophenyl)propan-1-ol 
• 1258879-09-2 N-[3-(3,4-dichlorophenyl)propyl]-N-hydroxyformamide 
• 63204-35-3 5-(3,4-dichlorobenzyl)-2-methylthio-4-pyrimidone 
• 63429-36-7 2-[2-(5-methyl-4-imidazolylmethylthio)ethylamino]-5-(3,4-dichlorobenzyl)-4-pyrimidone dihydrochloride 

Relevant academic research and scientific papers

7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS

The compounds of formula (I) are antagonists of the CCR2 receptor Wherein R1-7 and A are as defined in the claims.

7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS

The compounds of formula (I) are antagonists of the CCR2 receptor Wherein R1-7 and A are as defined in the claims.

NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY

The present invention generally concerns particular methods and compositions for antimicrobial therapy. In particuarl embodiments, the compositions target DXR. In specific embodiments, the compositions are electron-deficient heterocyclic rings.

Inhibition of uridine phosphorylase: Synthesis and structure-activity relationships of aryl-substituted 5-benzyluracils and 1-[(2- hydroxyethoxy)methyl]-5-benzyluracils

A series of 1-[(2-hydroxyethoxy)methyl]-5-benzyluracils were synthesized and tested for inhibition of murine liver uridine phosphorylase (UrdPase). Inhibitors of UrdPase are reported to enhance the chemotherapeutic utility of 5-fluoro-2'-deoxyuridine and 5-fluorouracil and to ameliorate zidovudine- induced anemia in animal models. We prepared a series of 5-aryl-substituted analogues of 5-benzylacyclouridine (BAU), a good inhibitor of UrdPase (IC50 of 0.46 μM), to develop a compound with enhanced potency and improved pharmacokinetics. The first phase of structure-activity relationship studies on a series of 32 aryl-substituted 5-benzyluracils found several 5-(3- alkoxybenzyl) analogues of 5-benzyluracil with enhanced potency. The acyclovir side chain, the (2-hydroxyethoxy)methyl group, was substituted on the more potent aryl-substituted 5-benzyluracils. The two most potent compounds, 10y (3-propoxy) and 10dd (3-sec-butoxy), were inhibitors of UrdPase with IC50s of 0.047 and 0.027 μM, respectively. Six compounds were tested in vivo for effects on steady-state concentrations of circulating uridine in rats. Plasma uridine levels were elevated 3-9-fold by compound levels that ranged from 8 to 50 μM.